PHARMASEAL International Ltd, a technology provider of clinical trial management and governance solutions for biopharmaceutical, CROs, and medical device organizations, and leading hybrid and decentralized trials software organization, Medrio have announced that they have entered into a partnership agreement.
“This partnership allows us to offer customers a fully integrated eClinical solution that supports trials in all phases. By joining forces with Medrio, we will simplify clinical trial management for customers with more user-friendly interfaces, reduced data duplication, and improved trial management visibility, along with the adaptability to suit the needs of different clinical trial designs” said Daljit Cheema, Founder & CEO at PHARMASEAL.
The combination of Medrio’s integrated platform of EDC, eConsent, ePRO, eCOA, Direct Data Capture, and RTSM with Engility®—PHARMASEAL’s dynamic CTMS, eTMF, and payments capabilities system—will streamline research by enabling collaboration, agile processes, and enhanced study oversight. Additional benefits include transparent interoperability between PHARMASEAL and Medrio’s eClinical solutions, real-time data sharing, and scalable workflows that support larger, later-phase studies.
“We’re thrilled to partner with PHARMASEAL to offer our customers a world-class CTMS and eTMF solution that seamlessly integrates with Medrio’s flexible data collection and management tools. Medrio customers expect innovative, agile, and high-quality solutions. PHARMASEAL meets those expectations while also mirroring our customer-first mindset and shared objective of simplifying trial complexities. At Medrio, we recognize the value of partnership and that together we are stronger. We are looking forward to continuing to deliver high-quality data and operational excellence to our customers alongside PHARMASEAL.” – Fred Martin, Chief Product Officer, Medrio
For more details about how PHARMASEAL and Medrio can support your next project please contact sales@medriostagepwa.wpengine.com
About PHARMASEAL
PHARMASEAL was founded in 2016 by a team of industry leaders who share a vision to create smarter technologies and innovative products for the improvement of human health. The company’s SaaS platform Engility® simplifies the management and control of clinical trials for biopharmaceutical, CRO, and medical device companies. Engility® utilizes advanced engineering offering enterprise management with rapid deployment, an intuitive user interface, and interoperability with other eClinical applications to optimize trial governance and oversight. For more details please visit www.pharmaseal.co
About Medrio
Take control of your clinical research and studies with Medrio’s full-service suite of eClinical Data Management solutions. We’ve been innovators in the clinical trial technology space since 2005, evolving alongside our customers to meet the demands of today’s world. Our integrated platform of EDC, DDC, eConsent, RTSM, and ePRO/eCOA are configurable to meet any trial needs—from traditional to hybrid, or fully remote studies. That’s why sponsors, CROs, and clinicians across all therapeutic areas have leveraged our adaptive, unified technology to power clinical trial breakthroughs and secure over 770 regulatory approvals.
Our robust suite of tools was designed to offer you full functionality—without complexity—so you can streamline your study builds and focus on what matters most: your patients. While other eClinical vendors make similar claims, few can deliver the same white-glove customer service paired with patient-centric, proven clinical trial technology. Discover the Medrio difference and see what makes us your most strategic and successful partner. Learn more at medrio.com.